CRVO
CervoMed Inc.
1W: -4.7%
1M: -15.7%
3M: -50.2%
YTD: -48.1%
1Y: -62.3%
3Y: -55.1%
5Y: -95.0%
$4.04
+0.12 (+3.06%)
After Hours: $4.06 (+0.02, +0.62%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$37.4M
52W Range3.58-14.97
Volume16,999
Avg Volume88,877
Beta-5.88
Dividend—
Analyst Ratings
Company Info
CEOJohn J. Alam
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2008-05-23
Websitecervomed.com
20 Park Plaza
Boston, MA 02116
US
Boston, MA 02116
US
617-744-4400
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Latest News
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
HC Wainwright Forecasts CervoMed FY2027 Earnings
CervoMed reports FY results
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Winton Matthew | A-Award | 30,000 | $4.80 | 2026-02-11 |
| Gregoire Sylvie | A-Award | 75,000 | $4.80 | 2026-02-11 |
| ELDER WILLIAM ROBERT | A-Award | 30,000 | $4.80 | 2026-02-11 |
| De Rosch Mark | A-Award | 30,000 | $4.80 | 2026-02-11 |
| Blackburn Kelly | A-Award | 30,000 | $4.80 | 2026-02-11 |